Nearly half of patients survive 2 years with bevacizumab, temozolomide, and radiotherapy-based glioblastoma regimen

✍ Scribed by RICHARD HYER

• Book ID: 118628304
• Publisher: Frontline Medical Communications, Inc.
• Year: 2010
• Tongue: English
• Weight: 58 KB
• Volume: 7
• Category: Article
• ISSN: 1548-5315
• DOI: 10.1016/s1548-5315(11)70584-8